graph Evidence gap map comparisons
pembrolizumab based treatment
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
Comparator:  vs paclitaxel followed by doxorubicin plus cyclophosphamide; 
Risk of bias:  low;   some concerns;   high;  NA;